Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin DE000BAY0017
Ticker BAYN.DE
Company BAYER
Currency
Price
Aware Investor Index (AII) 1.1481
Recommendation BUY
P/E 20.49
ROE 11.92 %
Capitalization 53,521,177,600 $
Dividend Yield 5.30 %
P/S 1.32
AII Position 251
P/E Position 279
ROE Position 306
Capitalization Position 174
Dividend Yield Position 78
Sales 35,015,000,000 €
10-Year Average Earnings 2,250,400,000 €
Shares Outstanding 872,107,808
Equity 18,875,000,000 €
Dividend per Share 2.8 €
Industry Pharmaceutical
Country Germany
BAYER Investor Relations Web Site http://www.investor.bayer.com/en/







Sales:

YEAR MONTH AMOUNT
2017 12 35,015,000,000.00 €
2016 12 34,943,000,000.00 €
2015 12 46,324,000,000.00 €
2014 12 42,239,000,000.00 €
2013 12 40,157,000,000.00 €
2012 12 39,760,000,000.00 €
2011 12 36,528,000,000.00 €
2010 12 35,088,000,000.00 €
2009 12 31,168,000,000.00 €
2008 12 32,918,000,000.00 €

Earnings:

YEAR MONTH AMOUNT
2017 12 2,900,000,000.00 €
2016 12 2,233,000,000.00 €
2015 12 4,110,000,000.00 €
2014 12 3,426,000,000.00 €
2013 12 3,189,000,000.00 €
2012 12 889,000,000.00 €
2011 12 1,125,000,000.00 €
2010 12 1,245,000,000.00 €
2009 12 2,226,000,000.00 €
2008 12 1,161,000,000.00 €

Equity:

YEAR MONTH AMOUNT
2017 12 18,875,000,000.00 €
2016 12 16,565,000,000.00 €
2015 12 24,265,000,000.00 €
2014 12 20,106,000,000.00 €
2013 12 13,888,000,000.00 €
2012 12 14,363,000,000.00 €
2011 12 13,888,000,000.00 €

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 872,107,808
2016 12 832,502,808
2015 12 826,947,808
2014 12 826,947,808
2013 12 826,947,808
2012 12 826,947,808
2011 12 826,950,000

 












Bloomberg News for BAYER:



Google News for BAYER:

The Pharma Letter - 10 Jun 2019
CStone and Bayer to trial CS1001 with regorafenib in multiple cancers
CStone and Bayer to trial CS1001 with regorafenib in multiple cancers ... with Bayer HealthCare LLC, a unit of Germany's Bayer (BAYN: DE).
The Pharma Letter - 4 Jun 2019
Bayer and Arvinas ink deal on human PROTAC therapies
Bayer and Arvinas ink deal on human PROTAC therapies ... now signed a collaboration with German pharma major Bayer (BAYN: DE), with the ...
FXStreet - 31 May 2019
Trump showing he not afraid of a multi-front trade war; European ...
Healthcare: Bayer [BAYN.DE] -2.5% (Los Angeles County sues company), SHL Telemedicine [SHLTH.CH] +5.5% (offer revised). - Industrials: ...
The Pharma Letter - 1 Jun 2019
New darolutamide data presented at ASCO 2019
Meeting in Chicago by Finnish drugmaker Orion Corp (Nasdaq OMX; ORNAV) and partner German pharma major Bayer (BAYN: DE).
The Pharma Letter - 31 May 2019
FDA approves sNDA for Xospata
There is also Bayer's (BAYN: DE) Nexavar (sorafenib), which is approved for other cancers but used off-label in AML. EvaluatePharma sell-side ...
The Pharma Letter - 24 May 2019
Ipsen to show off strides made in renal, liver and lung cancers at ...
... Ipsen drug in combination with Roche's (ROG: SIX) Tecentriq (atezolizumab), in a comparison with Bayer's (BAYN: DE) Nexavar (sorafenib).
The Pharma Letter - 15 Feb 2019
Bayer takes on full rights to Vitrakvi and BAY 2731954
German pharma and crop sciences major Bayer (BAYN: DE) has exercised its option, under a change-in-control clause in the collaboration ...
The Economist - 2 May 2019
German businessWhy so many big German companies are in trouble
On April 26th 56% of shareholders in Bayer, a chemicals conglomerate, censured Werner Baumann and his management team. Most German ...
Yahoo Finance - 13 May 2019
Bayer to pay $2 billion after losing suit that claims weedkiller ...
Bayer AG BAYN-DE on Monday was ordered by a Northern California jury to pay more than $2 billion to a couple who say they were diagnosed ...
The Pharma Letter - 6 Feb 2019
Bayer gets welcome win in US court
The US courts have not been a happy place for life sciences company Bayer (BAYN: DE) since acquiring agribusiness giant Monsanto due to ...


Back